News Article | April 18, 2017
An advanced water treatment membrane made of electrically conductive nanofibers developed at Masdar Institute was highlighted by Dr. Raed Hashaikeh, Professor of Mechanical and Materials Engineering at Masdar Institute, in his keynote speech during the 3rd International Conference on Desalination using Membrane Technology held last week in Spain. Self-cleaning membranes offer a critically needed solution to the problem of fouling, which is the unwanted build-up of organic and inorganic deposits on a membrane’s surface that reduces the membrane’s ability to filter impurities. Water treatment and purification membranes that can easily clean themselves when fouled could make pressure-driven membrane filtration systems used to treat and desalinate water more energy-efficient. “Keeping membranes clean, permeable and functional is a great challenge to membrane desalination technologies. When a membrane becomes fouled, its pores get blocked and its flux is severely reduced, which means that much less water can pass through the membrane at a constant pressure,” Dr. Hashaikeh explained. Conventional methods for cleaning fouled membranes involve expensive and harsh chemical treatments, and often lead to water treatment plant shut-downs, which can cost millions of dollars in lost operational hours. In the UAE, annual spending on desalination is already estimated to cost AED12 billion, indicating a pressing need for solutions that avoid costly shut-downs and treatments. In addition to posing a heavy financial burden, fouled membranes are also a sustainability issue, as once a membrane becomes fouled, the higher pressure needed to push water through clogged pores significantly increases the plant’s energy consumption. The harsh chemicals used to clean a fouled membrane are also bad for the environment and require neutralizing. Thus, finding a way to easily and quickly clean fouled membranes not only makes financial sense, but environmental sense. In a country like the UAE, where natural gas-powered thermal desalination produces over 80% of the country’s domestic water, innovative technologies like self-cleaning membranes to support a shift toward lower-energy and lower-cost membrane-based desalination are essential for achieving economic and environmental balance while meeting the UAE’s water demands. And now, Dr. Hashaikeh’s research group may have brought the UAE closer towards realizing a more sustainable and economic approach to membrane desalination through their research on the application of advanced nanofibers for enhanced, self-cleaning membranes. The group has leveraged the electrically conductive nature of a special kind of nanofiber, called carbon nanotubes (CNT). CNTs are tiny cylindrical tubes made of tightly bonded carbon atoms, measuring just one atom thick. But the CNTs Dr. Hashaikeh’s team used, which were provided by global security, aerospace, and information technology company Lockheed Martin, are not ordinary CNTs. “The carbon nanostructures supplied by Lockheed Martin are special; they are networked. This means that they are composed of many interconnecting channels that branch off in all directions. This interconnectivity is what enables the entire membrane to become completely cleaned when electricity is applied to it,” Dr. Hashaikeh said. The networked CNTs, also known as carbon nanostructures (CNS), coupled with the team’s expert membrane fabrication know-how, resulted in the development of two different types of membranes that can clean themselves when a low-voltage electric current is run through them. The first type is a microfiltration membrane, which has pores sizes ranging from 100 nanometers to 10 micrometers, where a nanometer is approximately one hundred thousand times smaller than the width of a human hair and a micrometer one thousand times larger than a nanometer. The second is a nanofiltration membrane with pore sizes ranging from one to ten nanometers. Both membranes demonstrated the ability to clean themselves in response to an electric shock, which resulted in the immediate restoration of the membranes’ flux. Dr. Hashaikeh’s investigation of a self-cleaning membrane began four years ago, when he realized that electrolytic cleaning – which is the process of removing soil, scale or corrosion from a metal’s surface by subjecting it to an electric current – could also be used to clean membranes. To prove his theory, he coated a membrane with ordinary CNTs. When a voltage was applied to the membrane, the parts of the membranes that were coated with CNTs were successfully cleaned. Dr. Hashaikeh filed a patent for this in-situ electrolytic cleaning process with the United States Patent and Trademark Office (USPTO) in 2014. However, there were limitations to this discovery, namely that only specific areas in the coated CNTs were cleaned, not the entire membrane. Thus, to develop an efficient, self-cleaning membrane with commercial potential, Dr. Hashaikeh required a material that would easily allow electric shockwaves to penetrate through the entire membrane’s surface area. The unique, interconnected structure of Lockheed Martin’s carbon nanostructures proved to be just the right type of electrically conductive, nano-fibrous material required. “We immediately recognized that Lockheed Martin’s CNTs might enable electricity to pass through the entire surface, but we had to modify the nanostructures to transform the material into a membrane. To do this, we controlled certain properties, such as wettability and pore size, and improved its mechanical strength by incorporating polymer materials,” he explained. Dr. Haishaikeh’s team successfully developed a self-cleaning microfiltration membrane in 2014 and a paper describing the research was published in the Journal of Membrane Science. But they did not stop there; they wanted to take their research a step further and find a way to develop a self-cleaning nanofiltration membrane. While microfiltration membranes are useful for removing larger particles, including sand, silt, clays, algae and some forms of bacteria, nanofiltration membranes can go a step further, removing most organic molecules, nearly all viruses, most of the natural organic matter and a range of salts. Nanofiltration membranes also remove divalent ions, which make water hard, making nanofiltration a popular and eco-friendly option to soften hard water. To create self-cleaning nanofiltration membranes out of Lockheed Martin’s networked CNTs, the team needed to overcome the problem of the CNTs’ large pore sizes, which prevented the material from functioning as a nanofiltration membrane. To achieve this they looked to a second advanced nanofiber material previously developed by Dr. Hashaikeh’s research group, known as networked cellulose. Networked cellulose is a modified type of cellulose made from wood pulp. When dried, the networked cellulose gel shrinks in volume, but maintains its integrity and shape, becoming harder as it shrinks. The research team asserted that the networked cellulose gel could reduce the membrane’s pore sizes while maintaining its structural integrity. The researchers then mixed the carbon nanostructures with the networked cellulose gel and as the mixture dried, the networked cellulose shrank. The shrinking of the network cellulose in turn pressurized the nanostructures in the membrane. The resulting membrane is strong with much smaller pore sizes. Dr. Hashaikeh reports that the pore size dropped from 60 nanometers to just three nanometers with the addition of the networked cellulose in a paper describing the study, which was published in the journal Desalination last month. Co-authors from Masdar Institute include PhD student Farah Ahmad and postdoctoral researcher Boor Lalia, along with Dr. Nidal Hilal of Swansea University. Dr. Hashaikeh’s prolific scientific contribution to the field of membrane desalination has led to his recent appointment as an associate editor for the journal Desalination; a position that is essential to the quality of the international journal and its peer review process. The innovative research conducted by Dr. Hashaikeh and the team will help position Abu Dhabi as a leader in membrane desalination research and technology development. This project has already yielded a patent filing, and is hoped to provide the emirate with novel intellectual property in the critical industry of desalination.
News Article | May 8, 2017
SAN JOSE, Calif.--(BUSINESS WIRE)--Western Digital Corp. (NASDAQ: WDC) today announced that the National Inventors Hall of Fame (NIHF), in partnership with United States Patent and Trademark Office (USPTO), has inducted founder and retired Chief Executive Officer of SanDisk1 Dr. Eli Harari into its 2017 class. Dr. Harari was recognized for his groundbreaking inventions that helped lead to the development and commercialization of flash storage. Dr. Harari was formally inducted during a ceremony last week at the National Building Museum in Washington, D.C. “The breakthrough storage technologies pioneered by Eli and his ability to recognize the broad applications for flash memory were instrumental in the creation of the flash industry and forever changed how we consume, store and share data,” said Steve Milligan, chief executive officer at Western Digital. “His ingenuity and bold vision helped to firmly establish the SanDisk® brand around the world. Eli truly embodies the title ‘innovator’ and I am sincerely honored to congratulate him on this prestigious achievement.” “Dr. Harari’s innovations and leadership played a pivotal role in the development and proliferation of flash memory,” said Dr. Siva Sivaram, executive vice president of memory technology at Western Digital. “The storage technologies he helped pioneer transformed the consumer electronics industry and continue to expand the possibilities of data in a wide range of new markets and technology areas, from the data center to the ‘Internet of Things’ (IoT). I am proud to congratulate my friend and role model, Eli, on this well-deserved accolade.” Dr. Harari and 14 other elite engineers, scientists and inventors were selected for induction into the NIHF for groundbreaking, patented inventions that had a “meaningful contribution to society”. Among his achievements, Dr. Harari co-invented System-Flash and invented the floating gate EEPROM, a significant innovation that enabled data storage in flash memory. This work served as the foundation for transforming flash memory into a highly versatile and portable mass-storage media, and led to the development and commercialization of the compact, low-cost flash memory that is today found in everything from smartphones and computing devices, to the data center, to “connected” IoT devices and more. “Dr. Harari’s important work in data storage has been fundamental to development of technologies that today are at the heart our digital lives,” said National Inventors Hall of Fame Chief Executive Officer Mike Oister. “We are proud to welcome to the National Inventors Hall of Fame Dr. Harari and the rest of this year’s new class of industry pioneers whose patented innovations have furthered our nation.” This year’s inductees and their notable innovations will be showcased in the NIHF Museum in Alexandria, Va. Inductees will also participate in NIHF educational programs and competitions that strive inspire and challenge the next generation of young inventors in the areas of science, technology, engineering and math (STEM). Since its founding in 1973, the NIHF has inducted more than 500 industry pioneers who have conceived, patented and advanced the greatest technological achievements in the United States. About Western Digital Western Digital is an industry-leading provider of storage technologies and solutions that enable people to create, leverage, experience and preserve data. The company addresses ever-changing market needs by providing a full portfolio of compelling, high-quality storage solutions with customer-focused innovation, high efficiency, flexibility and speed. Our products are marketed under the HGST, SanDisk and WD brands to OEMs, distributors, resellers, cloud infrastructure providers and consumers. Financial and investor information is available on the company's Investor Relations website at investor.wdc.com. 1 – SanDisk was acquired by Western Digital Technologies, Inc. in 2016. After founding SanDisk, Dr. Harari served as CEO for 22 years SanDisk is a registered trademarks or trademarks of Western Digital Corporation or its affiliates in the U.S. and/or other countries. Other trademarks, registered trademarks, and/or service marks, indicated or otherwise, are the property of their respective owners. © 2017 Western Digital Corporation or its affiliates. All rights reserved.
News Article | May 8, 2017
By adapting the interaction between several independent radar transmissions in real time, KAUST researchers have shown that it is possible to vastly improve target identification and range using multiple input, multiple output (MIMO) radar systems. Radar is used extensively in civilian and military aviation to identify and monitor aircraft movements and potential meteorological dangers as well as being a critical component of flight control and surveillance systems. Radar works by transmitting a radio signal from an output antenna and monitoring a receiving antenna for any detected reflections—akin to shining a spotlight into darkness to see what might be out there. Radar systems are now very sophisticated, and with advanced signal processing, it is now possible to discriminate between different types of objects from considerable distance. MIMO radar promises a step change in performance by being able to more adaptively shape the output waveform to concentrate the power of the transmitted signal in a specific direction and by transmitting multiple types of signal adapted to better match a broader range of targets. "MIMO radar uses several transmitting and receiving antennas at the same time, where the user can choose a different transmitted signal for each antenna," explained lead researcher and graduate student Taha Bouchoucha. "Our work was on the transmitter side, developing a simple way of constructing the transmitted waveforms to steer the signal to a specific region in space." There has been extensive research into MIMO radar systems, but the stumbling block has been the computational complexity of designing each individual waveform to produce the desired combined "beam pattern" after the waveforms have interacted in space. Under the supervision of Mohamed-Slim Alouini and Tareq Al-Naffouri, Bouchoucha focused on finding ways to simplify and accelerate these calculations. "We took advantage of a mathematical framework called the two-dimensional Fourier transform combined with fast and efficient algorithms to generate the Fourier transform parameters," said Bouchoucha. "Waveform generation using our approach is inexpensive and practical, and it gives complete flexibility and freedom to focus the transmitted signal in a specific region in space." The computation scheme has already been filed with the United States Patent and Trademark Office as a significant breakthrough in MIMO technology. "Being part of this project as a master's student was a great experience," said Bouchoucha, who is now a doctoral researcher at the University of California Davis. "It was an exceptional research environment, with inspiring mentors and peers who helped me develop." More information: Taha Bouchoucha et al. DFT-Based Closed-Form Covariance Matrix and Direct Waveforms Design for MIMO Radar to Achieve Desired Beampatterns, IEEE Transactions on Signal Processing (2017). DOI: 10.1109/TSP.2017.2656840
News Article | May 5, 2017
"Artificial intelligence and machine learning technologies are becoming core to next-generation service management and automation. There is now an even greater need for robust analytics across multiple data sources to uncover areas for automation and consistently measure and manage the quality of service delivery for both manual and automated workflows," said Stuart Evans, Distinguished Service Professor at Carnegie Mellon University. "I have been impressed with how Numerify's cloud-based solution fulfills this need for some of the largest and most demanding clients in the world." Numerify's product advancements are driven in part by two recent patent approvals from the United States Patent and Trademark Office around big data stores and metadata. Patent 9,619,535 allows for smart refreshes of data stores, in which reports and dashboards track actual customer usage of data stores. The smart data-store refreshes allow Numerify to support even challenging analytical scenarios in a cost-effective way without sacrificing data freshness. The second patent, 9,098,315, is a design for a metadata-driven web services connector that enables the extraction and processing of data from any cloud data source. Numerify also has 15 other patents pending in the areas of low-latency analytics of big data stores, analytics of workflow-based service-oriented processes, and metadata-driven approaches to cloud analytics. "With these technological enhancements, Numerify continues to expand its catalog of intellectual property and successfully augment the value of its analytical applications for innovative Fortune 2000 companies," said Srikant Gokulnatha, Co-Founder and Chief Product Officer of Numerify. "The company plans to continue leveraging innovative technologies around big-data analytics, machine learning, and AI in its mission to deliver end-to-end business analytics solutions that remain unmatched in the industry." Connect with Numerify at the upcoming ServiceNow® Knowledge17 conference, from May 7-11 at the Orange County Convention Center in Orlando, Florida. The company will also sponsor the Gartner IT Operations Strategies & Solutions Summit, which occurs during the same week at the Hilton in Orlando. About Numerify Numerify provides IT business analytics applications to leading organizations, including companies ranked in the top 5 across 10 major industries. The company's pre-built analytics solutions integrate data across various IT sources, contact center, and related business systems. Numerify's cloud applications rapidly deliver precise insights that help IT organizations optimize costs, increase innovation speed, and transform their service experience. Headquartered in San Jose, Calif., Numerify is backed by Lightspeed Venture Partners, Sequoia Capital, Tenaya Capital, Silicon Valley Bank, and Four Rivers Group. For more information, visit www.numerify.com or follow @numerify. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/numerify-expands-core-capabilities-of-its-business-analytics-platform-and-secures-new-patents-300452049.html
News Article | April 25, 2017
MADISON, Wis., April 25, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces the United States Patent and Trademark Office has granted a method of use patent for CLR 1501, CLR 1502 and an additional CLR 1401-boron-dipyrromethene analog for the detection of multiple cancer types. All of these compounds utilize Cellectar’s proprietary phospholipid drug conjugate (PDC) delivery platform. The recently issued patent, 9,616,140, outlines the method of use of these fluorophore compounds to detect a variety of solid tumors in patients, including melanomas, colorectal adenocarcinoma, uterine carcinoma, pancreatic carcinoma, ovarian adenocarcinoma, glioblastoma, clear cell carcinoma, and prostate adenocarcinoma. The current patent provides intellectual property protection through May 11, 2029. “We continue to successfully execute our plan to expand the company’s intellectual property portfolio to protect and enhance the value of our PDC pipeline assets, both in diagnostic and therapeutic applications,” said Jim Caruso, president and CEO of Cellectar. “While our focus continues to be the development of our therapeutic assets, specifically CLR 131, for the treatment of multiple myeloma and other hematologic malignancies, our platform assets offer significant additional opportunity in a variety of clinical applications.” About Phospholipid Drug Conjugates (PDCs) Cellectar’s product candidates are built upon its patented cancer cell-targeting delivery and retention platform of optimized phospholipid ether-drug conjugates (PDCs). The company deliberately designed its phospholipid ether (PLE) carrier platform to be coupled with a variety of payloads to facilitate both therapeutic and diagnostic applications. The basis for selective tumor targeting of our PDC compounds lies in the differences between the plasma membranes of cancer cells compared to those of normal cells. Cancer cell membranes are highly enriched in lipid rafts, which are glycolipoprotein microdomains of the plasma membrane of cells that contain high concentrations of cholesterol and sphingolipids, and serve to organize cell surface and intracellular signaling molecules. PDCs have been tested in more than 80 different xenograft models of cancer. About Cellectar Biosciences, Inc. Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase I clinical study in patients with relapsed or refractory multiple myeloma. In addition, the company has initiated a Phase II clinical study to assess efficacy in a range of B-cell malignancies. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information please visit www.cellectar.com. This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2016. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.
News Article | April 17, 2017
Texas Genius has announced that it is holding its Genius Awards ceremony to honor 50 most creative people and companies of Texas on Friday, April 21. The event will be held in conjunction with the World Intellectual Property Day, a day set aside around the globe to celebrate Creativity and Innovation. The honorees will have an opportunity to display their most recent patented products and registered trademarks. The awards ceremony will be held at the Sheraton Austin Hotel at the Capitol with a showcase starting at 6:30 pm followed by dinner at 7:30 pm with David Bradford, CEO & Co-Founder of FluentWorlds, as the keynote speaker. The Genius Awards program (www.texas-genius.com) is an annual event which celebrates Ideas, Creativity, and Innovation. It honors the Top 20 Texas inventors, the Top 20 Texas patent companies and the Top 10 Texas trademark registrants. It selects winners using data that comes directly from the United States Patent and Trademark Office. There is no voting nor nomination process; inventors and companies are determined each year by the number of patents issued or trademarks registered the previous year. It also grants an annual Lifetime Achievement Award to a Texan who has distinguished him or herself over the course of their career as an innovator and inventor and who has contributed to their community. World Intellectual Property Day is held every April 26 to celebrate the role that intellectual property rights (patents, trademarks, industrial designs, copyright) play in encouraging innovation and creativity. The 2017 theme for World Property Day is how innovation is making our lives healthier, safer, and more comfortable, turning problems into progress.
News Article | April 21, 2017
Receive press releases from The Knowledge Group: By Email P.J. McCarthy, Partner with Greenberg Traurig LLP to Speak at The Knowledge Groups ITC Section 337 Investigations: Your Thorough Guide for 2017 & Beyond New York, NY, April 21, 2017 --( For further details, please visit: https://knowgp.org/2nXuBhS About P.J. McCarthy Patrick J. McCarthy (PJ) is a patent litigator who is also barred and licensed to practice before the United States Patent and Trademark Office. PJ has litigated matters across a broad range of complex technologies, including semiconductor packaging and manufacturing, analog and digital integrated circuitry, smartphone hardware and software technology, telecommunications, global positioning systems, networking, distributed computing, internet search technology, vehicle collision systems, vehicle radar systems, cable and satellite set-top boxes, and satellite broadcasting. Those patent litigation matters have spanned federal district courts across the country, but also include numerous Section 337 Investigations at the International Trade Commission, where PJ concentrates much of his litigation practice. PJ is also experienced in briefing, managing, and arguing appeals to the United States Court of Appeals for the Federal Circuit. About Greenberg Traurig LLP Greenberg Traurig, LLP (GTLaw) is an international, multi-practice law firm with more than 2,000 attorneys across 38 offices in the United States, Latin America, Europe, Asia and the Middle East and is celebrating its 50th anniversary. A single entity worldwide, GTLaw is No. 1 on the 2015 Law360 Most Charitable Firms list, second largest in the U.S. on the 2016 Law360 400, and Top 20 on the 2016 Am Law Global 100. GT encourages attorneys to organize the cross-practice teams required to meet the needs of our clients. We provide our services with the dedication and responsiveness of a boutique firm and the breadth, depth, resources and operating efficiencies of one of the largest law firms in the United States. Abstract Section 337 of the Tariff Act of 1930 prohibits unfair methods of competition and practices in import trade, particularly the importation or sale of infringing goods in the United States. The U.S. International Trade Commission (ITC) Section 337 investigations involve high stakes for both patent holders and parties accused of importing infringing products. The complex and challenging ITC investigations demands for a multi-disciplined approach that involves knowledge of intellectual property litigation and international trade and policy. It is important for businesses and their counsel to understand the unique procedural framework of the ITC Section 337 investigations. The Knowledge Group has assembled a panel of key thought leaders and practitioners to discuss ITC Section 337 investigations and offer a thorough guidance to navigate the complexities of Section 337 proceedings. In a two-hour live webcast, the speakers will discuss: • Overview of Section 337 • ITC Section 337 Investigations Framework • Asserting Section 337 Claims • Issues and Challenges in a Section 337 Investigation • Recent Filing Trends at the ITC About The Knowledge Group/The Knowledge Congress Live Webcast Series The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/ New York, NY, April 21, 2017 --( PR.com )-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that P.J. McCarthy, Partner with Greenberg Traurig LLP will speak at The Knowledge Group’s webcast entitled: “ITC Section 337 Investigations: Your Thorough Guide for 2017 & Beyond.” This event is scheduled for May 3, 2017 from 12:00pm to 2:00pm (ET).For further details, please visit: https://knowgp.org/2nXuBhSAbout P.J. McCarthyPatrick J. McCarthy (PJ) is a patent litigator who is also barred and licensed to practice before the United States Patent and Trademark Office. PJ has litigated matters across a broad range of complex technologies, including semiconductor packaging and manufacturing, analog and digital integrated circuitry, smartphone hardware and software technology, telecommunications, global positioning systems, networking, distributed computing, internet search technology, vehicle collision systems, vehicle radar systems, cable and satellite set-top boxes, and satellite broadcasting. Those patent litigation matters have spanned federal district courts across the country, but also include numerous Section 337 Investigations at the International Trade Commission, where PJ concentrates much of his litigation practice. PJ is also experienced in briefing, managing, and arguing appeals to the United States Court of Appeals for the Federal Circuit.About Greenberg Traurig LLPGreenberg Traurig, LLP (GTLaw) is an international, multi-practice law firm with more than 2,000 attorneys across 38 offices in the United States, Latin America, Europe, Asia and the Middle East and is celebrating its 50th anniversary. A single entity worldwide, GTLaw is No. 1 on the 2015 Law360 Most Charitable Firms list, second largest in the U.S. on the 2016 Law360 400, and Top 20 on the 2016 Am Law Global 100.GT encourages attorneys to organize the cross-practice teams required to meet the needs of our clients. We provide our services with the dedication and responsiveness of a boutique firm and the breadth, depth, resources and operating efficiencies of one of the largest law firms in the United States.AbstractSection 337 of the Tariff Act of 1930 prohibits unfair methods of competition and practices in import trade, particularly the importation or sale of infringing goods in the United States. The U.S. International Trade Commission (ITC) Section 337 investigations involve high stakes for both patent holders and parties accused of importing infringing products. The complex and challenging ITC investigations demands for a multi-disciplined approach that involves knowledge of intellectual property litigation and international trade and policy. It is important for businesses and their counsel to understand the unique procedural framework of the ITC Section 337 investigations.The Knowledge Group has assembled a panel of key thought leaders and practitioners to discuss ITC Section 337 investigations and offer a thorough guidance to navigate the complexities of Section 337 proceedings.In a two-hour live webcast, the speakers will discuss:• Overview of Section 337• ITC Section 337 Investigations Framework• Asserting Section 337 Claims• Issues and Challenges in a Section 337 Investigation• Recent Filing Trends at the ITCAbout The Knowledge Group/The Knowledge Congress Live Webcast SeriesThe Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/ Click here to view the company profile of The Knowledge Group Click here to view the list of recent Press Releases from The Knowledge Group
News Article | April 17, 2017
Idaho Genius has announced that it is holding its Genius Awards ceremony to honor 50 of Idaho’s most creative people and companies on Thursday, April 27. The event will be held in conjunction with World Intellectual Property Day, a day set aside around the globe to celebrate Creativity and Innovation. The honorees will have an opportunity to display their most recent patented products and registered trademarks. The awards ceremony will be held at Boise’s Grove Hotel with a showcase starting at 6 pm followed by dinner at 7 pm. Cheryl SnappConner, CEO of SnappConner PR will be the keynote speaker. A Lifetime Achievement Award will be presented this year to Bob Lokken, Founder and CEO of WhiteCloud Analytics. The Genius Awards program is an annual event which celebrates Ideas, Creativity, and Innovation. It honors the Top 20 Idaho inventors, the Top 20 Idaho patent registrants and the Top 10 Idaho trademark registrants. It selects winners using data that comes directly from the United States Patent and Trademark Office. There is no voting nor nomination process; inventors and companies are determined each year by the number of patents issued or trademarks registered the previous year. It also grants an annual Lifetime Achievement Award to an Idahoan who has distinguished him or herself over the course of their career as an innovator and inventor and who has contributed to their community. World Intellectual Property Day is held every April 26 to celebrate the role that intellectual property rights (patents, trademarks, industrial designs, copyright) play in encouraging innovation and creativity. The 2017 theme for World Property Day is how innovation is making our lives healthier, safer, and more comfortable, turning problems into progress.
News Article | May 4, 2017
SUZHOU, China, 4. Mai 2017 /PRNewswire/ -- Stainwei Biotech, Inc. (Stainwei), ein chinesisches Biotech-Unternehmen im Biobay-Industriepark in Suzhou, China, gab heute bekannt, dass es eine Patenturkunde (Patent-Nr. US9.580.498) durch das US-amerikanische Patentamt, United States Patent and Trademark Office (USPTO), für seinen neuartigen humanisierten monoklonalen Anti-VEGF-Antikörper (mAb-Codename: hPV19) erhalten hat. Erteilt wurde dieses Patent auf dem Weg einer PCT-Anmeldung (PCT/CN2013/086542), die von Stainwei 2013 eingereicht worden war. Vor der Erteilung des US-Patents hat Stainwei bereits 2015 und 2016 zwei Patenturkunden für diesen Antikörper von der Staatlichen Behörde für Geistiges Eigentum der Volksrepublik China erhalten. Stainwei setzt sich für Innovationen und für die Entwicklung von neuartigen therapeutischen Antikörpermedikamenten ein, die auf die Behandlung von Krebserkrankungen, altersbedingter Makuladegeneration (AMD) und Erkrankungen des Immunsystems abzielen. Eine klinische Studie der Phase I, bei der die Sicherheit und Wirksamkeit von hPV19 bei Krebspatienten bewertet wird, läuft derzeit in China. Laut den vom Unternehmen veröffentlichten Daten verfügt hPV19 über eine einzigartige Antigenerkennungsstruktur (Epitop), die sich aus Aminosäuresequenzen zusammensetzt, die sich von anderen kommerziell verfügbaren, auf dieselben Antigene abzielenden Antikörpern unterscheiden. hPV19 hat sowohl in In-vitro- wie in In-vivo-Versuchen eine 6- bis 8-mal höhere biologische Aktivität als Avastin gezeigt (generischer Name: Bevacizumab, monoklonaler Anti-VEGF-Antikörper von Roche/Genentech, das weltweit erste und bislang immer noch einzige monoklonale Anti-VEGF-Antikörper-Medikament auf dem Markt, das von der FDA zugelassen wurde). „In den vorklinischen Studien und klinischen Frühphasen-Studien mit Krebspatienten hat hPV19 zudem ein ausgezeichnetes Profil in Sachen Sicherheit und Verträglichkeit gezeigt", sagte Dr. Qunmin Zhou, der Mitgründer des Unternehmens. „Wir sind seht gespannt darauf, seine Wirksamkeit in den laufenden klinischen Studien testen zu können. Außerdem warten wir auch mit Spannung darauf, dass wir hoffentlich ein einzigartiges Nicht-Biosimilar- und stärkeres Therapeutikum auf den Markt bringen, von dem unsere Patienten profitieren können."
News Article | April 18, 2017
COPENHAGEN, Denmark, April 18, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”), today reported financial results for the fourth quarter and year ended December 31, 2016. Net income for the fourth quarter December 31, 2016 was $9.6 million while net loss for the year ended December 31, 2016 was $33.3 million, or $0.20 and $(0.71) per diluted share, respectively. On a non-GAAP basis, after removing the effect of non-cash income and expense items, our fourth quarter and year ended 2016 net loss would have been $11.8 million and $40.9 million, or $(0.25) and $(0.87) per basic share, respectively. As of December 31, 2016, the Company had $138.7 million in cash, cash equivalents and marketable securities, with no debt outstanding. “We made substantial progress in creating shareholder value from our patent portfolio, most importantly signified by the Settlement and License Agreement with Biogen. We also received a ruling in the patent interference case with Biogen and are working diligently to advance the appeal to the Federal Circuit and prepare for the opposition proceeding for our European ‘355 patent in November,” said Dr. Claus Bo Svendsen, Chief Executive Officer of Forward. “Having received the $1.25 billion non-refundable payment from Biogen, we remain in the strongest financial condition in the history of the Company, positioning us to return significant near-term value to shareholders.” Fourth Quarter and Year Ended December 31, 2016 Financial and Operational Results The GAAP net loss for years ended 2016 and 2015 was $33.3 million and $37.0 million, respectively. The GAAP net income for the fourth quarter of 2016 was $9.6 million compared to a net loss of $9.6 million for the fourth quarter of 2015. Net income for the fourth quarter of 2016 includes a deferred tax benefit of $21.3 million primarily related to net operating loss carryforwards that will be utilized in 2017 based on our estimate that the Company will have taxable profits in 2017. Research and development expenses for the year ended 2016 and 2015 were $41.1 million and $33.7 million, respectively. Research and development expenses were $10.3 million for the quarter ended December 31, 2016 compared to $8.6 million for the fourth quarter of 2015. The increase in costs for the year ended 2016 compared to 2015 was primarily due to an increase in expenses to register and advance our intellectual property and higher share-based compensation. The increase in research and development expenses in the fourth quarter of 2016 versus the same period in 2015 was due to an increase in patent related costs. We estimate that research and development costs will decrease in 2017 compared to 2016 as our development efforts for FP187 will be limited to finishing the work that was in process prior to entering into the License Agreement with Biogen discussed below. General and administrative expenses for the year ended 2016 and 2015 were $14.4 million and $15.9 million, respectively. General and administrative expenses were $5.1 million for the quarter ended December 31, 2016 compared to $3.6 million for the fourth quarter of 2015. The decrease in costs for the year ended 2016 compared to 2015 was principally due to a $1.2 million reduction in share based compensation. The increase in general and administrative expenses in the fourth quarter of 2016 versus the same period in 2015 was primarily due to professional fees. We expect our general and administrative costs will remain at current levels; however, expenses associated with protecting, defending and enforcing our patent rights that occur in the courts could increase in future periods. Non-cash stock based compensation expense included in total operating expenses was $14.3 million for the year ended 2016 versus $13.5 million for the year ended 2015. As of December 31, 2016, the Company had $138.7 million in cash, cash equivalents and marketable securities. On January 17, 2017, Forward announced that it entered into a binding agreement with two wholly owned subsidiaries of Biogen and certain additional parties to enter into a Settlement and License Agreement (the “License Agreement”). In February 2017, Forward received a non-refundable cash fee of $1.25 billion from Biogen in connection with the License Agreement. During February and March 2017, to reduce the Company’s exposure to changes in foreign exchange rates, the Company converted the $1.25 billion into 1.17 billion Euros. On March 31, the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office (“USPTO”) issued a decision in favor of Biogen in Patent Interference No. 106,023 regarding claims of Forward Pharma’s patent application 11/576,871 (the “’871 application”) that cover a method of treating multiple sclerosis (“MS”) using a 480 mg per day dose of dimethyl fumarate (“DMF”), the approved dose of Tecfidera®. We intend to appeal this decision. If Forward Pharma ultimately prevails in the interference after all appeals to the U.S. Court of Appeals for the Federal Circuit (“Federal Circuit”), and the ’871 application issues with claims covering treatment for MS by orally administering 480 mg per day of DMF, we anticipate that Biogen would be obligated to pay future royalties on net sales in the U.S. of Biogen’s DMF-containing products, including Tecfidera®, indicated for treating MS that would, but for the rights granted under the License Agreement, infringe a Company patent, provided that other conditions of the License Agreement are satisfied. Among the conditions that needs to be satisfied for any royalty to be payable by Biogen to us on net sales in the U.S. is the absence of generic entry in the U.S. having a particular impact as defined by the License Agreement. If Forward Pharma succeeds in the interference as described above and Biogen obtains an exclusive license to all intellectual property in the United States that is owned by Forward Pharma (the “U.S. Licensed Intellectual Property”) under the License Agreement and other conditions are satisfied, a royalty of 10% would be payable by Biogen on net sales in the U.S. of applicable infringing products from January 1, 2021 to December 31, 2028 (increasing to 20% from January 1, 2029) until the earlier of the expiration or invalidation of the patents owned by Forward Pharma in the U.S. Biogen’s existing perpetual, irrevocable, co-exclusive license to all of the U.S. Licensed Intellectual Property will be converted into an irrevocable exclusive license to all of the U.S. Licensed Intellectual Property if all of the terms and conditions of the License Agreement are met within the time period set forth in the License Agreement, including the absence of legal restraints and termination or expiration of any required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. If Biogen does not obtain an exclusive license, and provided that other conditions of the License Agreement are satisfied, Biogen will maintain a co-exclusive license with respect to the U.S. Licensed Intellectual Property, and the royalties payable by Biogen to Forward Pharma on its net sales in the U.S. of applicable infringing products would instead be 1% from January 1, 2023, and Forward Pharma would retain the right to commercialize in the U.S. or assign its U.S. co-exclusive rights, on one occasion only, to a single third party. If we prevail after all appeals to the Federal Circuit, we expect our ’871 application, if ultimately issued, would be entitled to patent term adjustment extending the patent term to compensate the Company for time lost during prosecution and the interference, which the Company estimates would result in patent expiration in 2029 or later. The hearing for the pending opposition proceeding against the Company’s European patent EP2801355 (“Opposition Proceeding”) is currently scheduled for November 6 and 7, 2017. If the Company obtains, as a result of the Opposition Proceeding, and any appeals therefrom, a patent with a claim covering oral treatment of MS with 480 mg per day of DMF, it would be eligible beginning on January 1, 2021 to collect a 10% royalty (increasing to 20% from January 1, 2029) until the earlier of the expiration or invalidation of the patents defined in the License Agreement, on a country-by-country basis on Biogen’s net sales outside the U.S. of DMF-containing products, including Tecfidera®, indicated for treating MS that, but for the rights granted under the License Agreement, would infringe a Company patent, provided that other conditions of the License Agreement are satisfied. Among the conditions that needs to be satisfied for any royalty to be payable by Biogen to us in a particular country is the absence of generic entry in that country having a particular impact as defined in the License Agreement. On March 1, 2017, the Company announced plans to finish its remaining research and development efforts and to pursue an organizational realignment to reduce personnel and operating expenses. We are currently finishing the research and development work that was in process prior to the effective date of the License Agreement and thereafter plan to suspend further development of our clinical candidate, FP187, pending the outcome of the appeal to the Federal Circuit regarding the decision in the interference with Biogen, and whether or not Biogen obtains an exclusive license in the U.S. If Biogen maintains a co-exclusive license, we expect to either assign our co-exclusive license rights to a single third party on one occasion only or reinitiate development of FP187, or initiate development of another DMF-containing formulation, in anticipation of a regulatory submission to the FDA. However, if Biogen prevails in the interference and IPR brought by the Coalition for Affordable Drugs, after any appeals to the Federal Circuit, we may be prevented from commercializing our lead product candidate, FP187, for MS in the U.S. at a 480 mg per day dose. Although we have previously released financial results on a quarterly basis, consistent with our plan to reduce expenses, we intend to release future financial results semi-annually, with our next report following the end of our second quarter. USPTO interference with Biogen: The related documents are publicly available on the USPTO interference website at https://acts.uspto.gov/ifiling/PublicView.jsp, using interference number 106023. Forward Pharma U.S. and European patents and patent applications can be found by using the following links: USPTO: http://www.uspto.gov/ USPTO Public PAIR: http://portal.uspto.gov/pair/PublicPair EPO: https://register.epo.org/regviewer About Forward Pharma: Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company owns a significant intellectual property (IP) portfolio related to DMF formulations. The Company granted to Biogen an irrevocable license to all of its IP through the recent License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, the anticipated appeal of the U.S. interference and the EP2801355 opposition outcome in Europe. Our principal executive offices are located at Østergade 24A, 1st Floor, 1100 Copenhagen K, Denmark and our American Depositary Shares are publicly traded on NASDAQ Stock Market (FWP). For more information about the Company, please visit our web site at http://www.forward-pharma.com. Forward Looking Statements: Certain statements in this press release may constitute “forward-looking statements” of Forward Pharma A/S (the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements which contain language such as “believe,” “expect,” “anticipate,” “hope,” “would”, “may”, and “potential.” Forward-looking statements are predictions only, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, risks related to the following: the satisfaction of certain conditions, and the accuracy of certain representations of the Company, in the License Agreement entered into with subsidiaries of Biogen Inc. and certain other parties thereto; our ability to obtain, maintain, enforce and defend issued patents with royalty-bearing claims; our ability to successfully appeal the interference decision to the Federal Circuit; our ability to prevail in or obtain a favorable decision in the Opposition Proceeding, after all appeals; the issuance and term of our patents; future sales of Tecfidera®, including impact on such sales from competition, generic challenges, regulatory involvement and pricing pressures; the scope, validity and enforceability of our intellectual property rights in general and the impact on us of patents and other intellectual property rights of third parties; the timing, amount (if any) and tax consequences of any distribution to shareholders; and our ability to generate revenue from product sales in the U.S. directly or through an assignee of our U.S. co-exclusive license rights in the event Biogen does not obtain an exclusive license from us in the U.S. Certain of these and other risk factors are identified and described in detail in certain of our filings with the United States Securities and Exchange Commission, including our Annual Report on Form 20-F for the year ended December 31, 2016. We are providing this information as of the date of this release and do not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.